New drug combo may help hepatitis b patients stop daily pills
NCT ID NCT07135349
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tests a new injectable drug (BW-20507) combined with pegylated interferon in 209 adults with chronic hepatitis B. The goal is to see if this combination can lower hepatitis B virus markers enough to let patients safely stop their daily antiviral medication. Participants must have had hepatitis B for at least 6 months and meet specific blood test criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Argo Investigative Site
Hefei, Anhui, 230022, China
-
Argo Investigative Site
Beijing, Beijing Municipality, 100015, China
-
Argo Investigative Site
Sichuan, Chengdu, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, 400000, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, China
-
Argo Investigative Site
Fuzhou, Fujian, 350000, China
-
Argo Investigative Site
Guangzhou, Guangdong, 510515, China
-
Argo Investigative Site
Shenzhen, Guangdong, 518000, China
-
Argo Investigative Site
Zunyi, Guizhou, 563000, China
-
Argo Investigative Site
Changzhou, Jiangsu, 213000, China
-
Argo Investigative Site
Xuzhou, Jiangsu, 22100, China
-
Argo Investigative Site
Nanchang, Jiangxi, 330000, China
-
Argo Investigative Site
Jiangxi, Nanchang, China
-
Argo Investigative Site
Shanghai, Shanghai Municipality, 2000001, China
-
Argo Investigative Site
Chengdu, Sichaun, 610041, China
-
Argo Investigative Site
Chengdu, Sichuan, 610041, China
-
Argo Investigative Site
Zhejiang, Wenzhou, China
-
Argo Investigative Site
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.